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Background: The risk of cardiovascular disease is tremendously high in dialysis patients. Dialysis patients treated
with vitamin D analogs show decreased cardiovascular morbidity and mortality compared with untreated patients.
We examined the influence of two common vitamin D analogs, alfacalcidol and paricalcitol, on important
cardiovascular biomarkers in hemodialysis patients. Anti-inflammatory effects and the influence on regulators of
vascular calcification as well as markers of heart failure were examined.
Methods: In 57 chronic hemodialysis patients enrolled in a randomized crossover trial comparing paricalcitol and
alfacalcidol, we examined the changes in osteoprotegerin, fetuin-A, NT-proBNP, hs-Crp, IL-6 and TNF-α, during
16 weeks of treatment.
Results: NT-proBNP and osteoprotegerin increased comparably in the paricalcitol and alfacalcidol-treated groups.
Fetuin-A increased significantly in the alfacalcidol-treated group compared with the paricalcitol-treated group
(difference 32.84 μmol/l (95% C.I.; range 0.21–67.47)) during the first treatment period. No difference was found
between the groups during the second treatment period, and IL-6, TNF-α and hs-Crp were unchanged in both
treatment groups.
Conclusions: Paricalcitol and alfacalcidol modulate regulators of vascular calcification. Alfacalcidol may increase the
level of the calcification inhibitor fetuin-A. We did not find any anti-inflammatory effect or difference in changes of
NT-proBNP.
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Cardiovascular mortality in hemodialysis patients is tre-
mendously high compared with the general population
[1]. Vitamin D deficiency is associated with increased risk
of cardiovascular disease and mortality in hemodialysis
patients [2-5]. Observational studies have shown that
hemodialysis patients treated with vitamin D analogs have
an increased survival [6,7]. It has been proposed that the
survival advantage differs between various vitamin D
analogs [8].
The mechanism of cardiovascular protection by vitamin
D analogs has been proposed to be due to anti-
inflammatory properties [9], modulation of calcification
factors and interaction in the bone-vascular crosstalk
[10,11], and modulation of cardiac structure and function
[12-14].
In order to explore the influence of vitamin D analogs
in hemodialysis patients, we examined the changes in in-
flammation (hs-Crp, IL-6 and TNF-α), cardiac function
(Nt-proBNP) and calcification factors (fetuin-A and osteo-
protegerin) during treatment with the vitamin D analogs
alfacalcidol and paricalcitol, and the possible differences
between the effects of these analogs.
Methods
Subjects
Subjects in this study were a subset of participants (57 of
86 enrolled patients), in a multicenter, open-label, 1:1 ran-
domized, crossover study comparing alfacalcidol and pari-
calcitol (SHPT-study). These subjects and the primary
results of the study have been described elsewhere [15,16];
in brief, adults receiving chronic hemodialysis therapy
with well-controlled calcium and phosphate levels, and
secondary hyperparathyroidism (p-iPTH >350 pg/ml)
received alfacalcidol or paricalcitol for 16 weeks in order
to control the secondary hyperparathyroidism.
Only participants from whom blood had been collected
during the entire trial period were included. The entire
study population did not have blood sample collection
because of: 1) improper collection at study sites; 2) partici-
pants refusing to participate in Biobank collection; and
3) withdrawal from the original study.
The study was in compliance with the Helsinki Declar-
ation of 1975, revised in 2000, and was approved by the
Danish National Committee on Biomedical Research
Ethics (SJ-27). All participants had received written and
oral information prior to the study and had given written
informed consent.
Design
The design has been described previously and discussed in
detail [15]. The study took place in 10 public Danish dialy-
sis departments, all being a part of hospital nephrology
departments. The randomization was performed after a6-week washout period. The first arm received alfacalcidol
for 16 weeks and then went through another 6-week
washout period before they received paricalcitol for
16 weeks. The second arm received paricalcitol for
16 weeks followed by a 6-week washout period before they
received alfacalcidol for 16 weeks. The starting dose of
alfacalcidol (Etalpha®Injection) was 3 μg per week and the
starting dose of paricalcitol (Zemplar®Injection) was 9 μg
per week. Every second week the dose was titrated 50%
according to p-phosphate, p-calcium and p-iPTH. As long
as p-phosphate was <1.8 mmol/l, ionized p-calcium was
<1.30 mmol/l and p-iPTH was >150 pg/ml, the dose was
increased. When p-iPTH was ≤150 pg/ml, p-phosphate
was <1.8 mmol/l and ionized p-calcium was <1.35 mmol/l,
the dose was maintained. If at any time p-phosphate was
>1.8 mmol/l or ionized p-calcium was >1.35 mmol/l in
two repeated measurements, the dose was reduced. The
minimal dose of alfacalcidol was 1.5 μg/week and that of
paricalcitol was 4.5 μg/week. If further reduction was
needed, treatment was paused.
After inclusion, the dose of calcium-containing phosphate-
binders could only be reduced or left unchanged. Elevated
p-phosphate levels were treated thoroughly with calcium-
free phosphate-binders, dietary intervention and re-
evaluation of the dialysis dose. Elevated p-calcium would
lead to dietary intervention and reduction of calcium con-
taining phosphate binders. The calcium concentration of
the dialysate was fixed at 1.25 mmol/l.
Blood samples were collected at the beginning (weeks 6
and 22) and at the end (weeks 28 and 44) of each treat-
ment period, separated by a 6-week washout period. Blood
samples were drawn from blood lines of the dialyzer
before the start of dialysis. Samples were frozen and col-
lected at Roskilde County Hospital. At the end of the
study, samples were aliquoted and cooled, and sent to
Odense University Hospital or Rigshospitalet for analysis.
Osteoprotegerin (OPG)
Plasma OPG was measured using a sandwich enzyme-
linked immunoabsorbent assay (ELISA) with commer-
cially available antibodies (R&D Systems, Minneapolis,
MN) and modified antibodies as previously described
[17,18]. In summary, mouse anti-human OPG was used as
the capture antibody, and a biotinylated goat anti-human
OPG, in combination with an Eu-labeled streptavidin, was
used for detection. Recombinant human OPG was used
for calibration and the analytical range of the assay was
62.5–4,000 pg/ml. Washing steps were performed on an
automated wash system (1296-026 Delfia Platewasher,
Wallac, Waltham, MA, USA) and optical densities were
determined at 450 nm on a VICTOR X5 Multimode Plate
Reader (Perkin-Elmer, Waltham, MA, USA). Data were
plotted with a four-parameter logistic (4PL) curve fit of
OD readings using GraphPad Prism software (version 5;
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cient of variation was 3%, and the inter-assay variation
was 8% in duplicate measurements.
Fetuin-A
A commercially available ELISA kit for human fetuin-A
with monoclonal antibodies (R&D Quantikine, catalog no.
DFTA00) was used. NS0-expressed recombinant human
fetuin-A was used for calibration and plasma was mea-
sured in a 4,000-fold dilution to read within the linear
range of the standard curve (75–1,000 pg/ml). Washing
steps were performed on an automated wash system
(1296-026 Delfia Platewasher) and optical densities were
determined at 450 nm on a VICTOR X5 Multimode
Plate Reader (Perkin-Elmer). Data were plotted with a
four-parameter logistic (4PL) curve fit of OD readings
using GraphPad Prism software (version 5; GraphPad
Software). Our intra-assay coefficient of variation was
5%, and the inter-assay variation was 9% in duplicate
measurements.
N-terminal pro-brain natriuretic peptide (NT-proBNP)
Measurement of NT-proBNP was done with a Cobas
e411 instrument (Roche). Imprecision of the analysis was
below 10%.
High-sensitivity C-reactive protein (Hs-Crp)
Hs-Crp was measured on an Architect C8000 (Abbott
Laboratories, Chicago, USA) using the latex immunoassay
Crp Vario (Sentinel Diagnostics, Milan, Italy). Reaction
parameters were applied to the Architect C8000 system as
recommended by the supplier. Within-run/between-run
coefficients of variations for the Crp Vario assay on the
C8000 were <2.3% and <4.3%, respectively.
Interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α)
An electro-chemiluminescence multiplex system was used
on a Sector 2400 Imager from Meso Scale Discovery
(Gaithersburg, MD, USA) according to the manufacturer’s
instructions. IL-6 and TNF-α were measured using a
multiplex system. All samples were run as duplicates.
Fibroblast growth factor (FGF-23)
FGF23 was measured using a sandwich enzyme-linked
immunosorbent assay (Kainos Laboratories Inc., Tokyo,
Japan), which detects only the biologically active intact
FGF23. The intra- and inter-assay coefficients of vari-
ation were less than 5.0%.
Other laboratory parameters
P-iPTH, ionized p-calcium and p-phosphate were mea-
sured every second week during treatment periods in
order to guide dose adjustments. These were then ana-
lyzed at participating department local laboratories.Statistical analysis
The distribution of variables and changes in the variables
from the start until the end was described. Continuous
data were described as mean (standard deviation or SEM)
if normally distributed or median (range) if not. Categor-
ical data were described as numbers and percentages.
Comparison of changes between groups were performed
according to Altman et al. [19]. Parametric tests were
used if the distributions were normal (paired and unpaired
t-tests) and non-parametric tests (Fischer’s Exact test,
Mann-Whitney U and Wilcoxon signed-rank test) were
used for ordered or continuous data. NT-proBNP and hs-
Crp were logarithmic transformed in order to reach nor-
mality. Explanatory factors for changes in OPG, fetuin-A
and NT-proBNP were found using multivariate analysis of
repeated measurements with backward selection. In order
to explore whether the presence of infection influenced
the inflammatory markers, patients experiencing at least
one adverse event of infection during the study were cen-
sored, and the data were analyzed in remaining patients.
All tests were two-sided tests (α = 0.05). Analysis was per-
formed using the SAS 9.1 software package (SAS Institute
Inc., Cary, NC, USA).
Results
Patient characteristics
In 57 patients, blood samples from all four visits during
the randomized controlled SHPT study were available
(Figure 1). There was no difference between patient
characteristics of the present study and enrolled pa-
tients in the SHPT study [16]. There was no difference
in patient characteristics between treatment groups
(Table 1).
Changes in mineral metabolism
Changes in. iPTH, ionized calcium and phosphate (FGF23
has been reported previously [16,20]).
Changes in NT-proBNP, OPG, fetuin-A, IL-6, TNF-α
and hs-Crp are shown in Table 2.
Calcification modulators
Fetuin-A
There was a significant period effect on fetuin-A changes
(P = 0.01). Therefore, we did not proceed to do any further
tests on the effects in the crossover population. The
results of each period are presented in Table 2.
There was a significant difference in changes in fetuin-A
between alfacalcidol and paricalcitol in period 1, owing to
a significant increase in fetuin-A in alfacalcidol-treated
patients. There were no significant changes within
groups or significant differences between groups during
period 2.
Changes in fetuin-A were logarithmically transformed
to satisfy the normality criterion of the parametric tests
Figure 1 Patients flow diagram.
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phosphate, PTH, FGF23 and hs-Crp using multiple linear
regression with backward selection. We found a signifi-
cant association only between changes in the log of fetuin-
A and changes in hs-Crp (Figure 2).OPG
OPG levels in one patient were considered as outliers, as
this patient presented extreme measurements that mark-
edly influenced the result. This patient was excluded from
further analysis. The patient did not differ from the other
Table 1 Baseline characteristics
Alfacalcidol-paricalcitol Paricalcitol-alfacalcidol
n = 26 n = 31
Age (years ± SD) 66.7 ± 10.8 67.1 ± 13.1
Gender (male/female) 17/9 17/12
Race: Caucasian 26(100%) 29(100%)





Chronic glomerulonephritis 5(19%) 4(14%)






Ischemic heart disease 9(35%) 10(34%)
Stroke or TCI 3(12%) 7(24%)
Heart failure 4(15%) 4(14%)
Biochemical
s-FGF23 (pg/ml (median (range))) 2952(95-25543) 2480(117-32650)
p-intact PTH (pg/ml ± SD) 568(246) 523(175)
p-calcium ion (mmol/l ± SD) 1.16(0.08) 1.15(0.08)
p-phosphate (mmol/l ± SD) 1.50(0.23) 1.49(0.27)
p-25hydroxyvitamin D2 + D3 (nmol/l ± SD) 43.4(24.3) 34.3(22.0)
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levels, adverse events or concomitant medication.
No significant period effect or treatment period inter-
action was found (P = 0.33 and P = 0.18, respectively).
Therefore, we proceeded with the analysis for treatment
effect. No difference in OPG response between treat-
ment groups was found (P = 0.94).
During period 1, there was a significant increase in
OPG in both treatment groups. During period 2 only the
alfacalcidol-treated patients had a statistically significant
increase in OPG. There was no statistically significant
change in OPG during the washout period in either
treatment group.
There was no difference in OPG levels between alfa-
calcidol and paricalcitol treatment groups at any time
(Table 2).
Multiple linear regression for repeated measurements
was performed to identify factors associated with
changes in OPG. Changes in OPG were normally dis-
tributed when inspecting histograms and probability
plots. No relation between treatment, period, mean finalequipotent dose of the vitamin D analog, changes in ion-
ized calcium, phosphate, FGF23 or alkaline phosphatase
were found. Equipotent doses of vitamin D analogs were
calculated by multiplying the alfacalcidol dose by a fac-
tor of 3, because the alfacalcidol:paricalcitol dose-ratio
was 1:3. The only factor significantly associated with
changes in OPG was the percentage of change in PTH
(Figure 3).
NT-proBNP
NT-proBNP was logarithmically transformed to satisfy
the normality criterion of the parametric tests. No
period effect (p = 0.12) or treatment-period interaction
(p = 0.07) was found. Therefore, we proceeded to the test
of difference between treatment groups and found no
significant difference in changes in NT-proBNP between
groups (p = 0.15).
During treatment period 1 there was a significant in-
crease in log NT-proBNP in the alfacalcidol-treated
group (p < 0.001) and in the paricalcitol-treated group
(p < 0.0001).
Table 2 NT-proBNP, inflammatory markers, osteoprotegerin and fetuin-A during treatment with vitamin D analogs


































































































Log hs-Crp 1.86 (1.20)
N = 24
















IL-6 (pg/ml) 6.99 (5.34)
N = 21
















TNF-α (pg/ml) 6.63 (2.45)
N = 23






















































































Distribution of NT-proBNP and hs-Crp was skewed and analyses were done by Mann-Whitney two sample test and presented with Hodge-Lehman median (95% confidence interval).
Logarithmic transformed NT-proBNP and hs-Crp and the remaining parameters were compared using an unpaired t-test and presented with the mean difference (95% confidence intervals).



















Figure 2 Changes in log fetuin-A according to changes in hs-Crp. Univariate analysis of changes in log fetuin-A as an independent variable
versus changes in hs-Crp during 16 weeks of treatment with paricalcitol and alfacalcidol.
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increase in log NT-proBNP in the alfacalcidol-treated
group (p = 0.08) and a non-significant decrease in the
paricalcitol-treated group (p = 0.09).
During washout, there were no significant changes in
the alfacalcidol-paricalcitol-treated group (p = 0.80), al-
though in paricalcitol-alfacalcidol-treated patients there
was a significant decrease in log NT-proBNP (p < 0.05 =
0.0468).
There was no significant difference in changes in NT-
proBNP during period 1 in patients with known heart
insufficiency at baseline (n = 9) compared with patients
with no history of heart insufficiency (n = 46) at baseline
(P = 0.22).
There was no correlation between changes in NT-




Four patients had hs-Crp levels above 100 mg/l. All of
them had a concomitant infection. These four patientsFigure 3 Changes in osteoprotegerin according to changes in parath
an independent variable versus changes in parathyroid hormone during 16(two in the alfacalcidol-paricalcitol group and two in the
paricalcitol-alfacalcidol group) were excluded from ana-
lysis because the intention was to describe hs-Crp as an
inflammatory marker.
The data were logarithmically transformed in order to
reach normality. There was no period effect (P = 0.40)
or significant treatment-period interaction (P = 0.93).
There was no difference between treatment effects
(P = 0.76).
IL-6
Patients with hs-Crp levels above 100 mg/l who also had
high IL-6 levels were deemed outliers and these patients
were censored.
There was no period effect (P = 0.85) or significant
treatment-period interaction (P = 0.55). There was no
difference between treatment effects (P = 0.37).
TNF-α
There was no period effect (P = 0.85) or significant
treatment-period interactions (P = 0.84) and there was
no difference between treatment effects (P = 0.36). Theyroid hormone. Univariate analysis of changes in osteoprotegerin as
weeks of treatment with paricalcitol and alfacalcidol.
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treatment periods are shown in Table 2.
There were no significant changes in any of the in-
flammatory markers even after excluding the patients
having an infection during the study (n = 11 alfacalcidol-
paricalcitol and n = 14 paricalcitol-alfacalcidol).
Discussion
We found no differences between alfacalcidol and
paricalcitol and their influence on NT-proBNP, OPG or
inflammatory markers during 16 weeks of treatment in
hemodialysis patients. Fetuin-A increased significantly in
the alfacalcidol-treated group compared with the
paricalcitol-treated group during the first treatment
period. Owing to a significant period effect we could not
analyze crossover data for differences in changes in
fetuin-A.
Fetuin-A was shown in experimental studies to be an
inhibitor of vascular calcification [21,22] and low levels of
fetuin-A have been associated with increased cardiovascu-
lar morbidity and mortality in dialysis patients [23-25]. It
is unknown whether an increase in fetuin-A level, as
found in the present study, protects against cardiovascular
disease.
Fetuin-A is known to be a negative acute phase react-
ant [26], and in accordance with former cross-sectional
studies in dialysis patients demonstrating a negative as-
sociation between levels of Crp and fetuin-A [25,27], we
even found a negative correlation between changes in
these parameters. This points to fetuin-A being part of
the malnutrition-inflammation-atherosclerosis syndrome
in dialysis patients.
We found an increase in fetuin-A during the first
treatment period in both groups. This increase was only
statistically significantly higher in the alfacalcidol-treated
group compared with the paricalcitol-treated group.
However, a significant increase in fetuin-A during pari-
calcitol treatment has been demonstrated after eight
weeks of treatment in an uncontrolled study in
hemodialysis patients [28]. There was a tendency to-
wards a higher prevalence of patients with diabetes at
baseline in the paricalcitol-treated group. This may
modulate changes in fetuin-A, as diabetic patients had
higher fetuin-A levels and may respond differently than
non-diabetic patients [29,30]. The discrepancy between
the effects in period 1 and period 2 could be due to a
carryover effect from the first treatment period, or the
significant difference during period 1 may simply be due
to chance. The actual effect of vitamin D analogs on
fetuin-A remains to be demonstrated in a placebo-
controlled trial.
Alfacalcidol and paricalcitol appeared to increase
OPG. This increase may be due to a direct effect of vita-
min D analogs or to suppression of parathyroidhormone, which was found to correlate with changes in
OPG. Because PTH decreased least in the paricalcitol-
treated patients during the second treatment period, this
may explain why OPG did not show any significant
changes during this period. The changes in OPG during
vitamin D analog treatment have, as far as we know,
only been studied in an uncontrolled trial of maxacalci-
tol, where the opposite effects were found, namely that
this led to a decrease in OPG [31].
OPG is an important factor in bone metabolism where
OPG acts as a decoy receptor for receptor activator of
nuclear factor кB (RANK) ligand (RANKL) and inhibits
activation of RANK, inhibits maturation of osteoclasts
and prevents bone resorption [32]. In animal models,
OPG deficiency causes vascular calcification [33] and
OPG treatment has been shown to block vascular calcifi-
cation [34]. However, in dialysis patients, OPG has been
associated with calcification and the progression of calci-
fication [35-37]; both in the general population and in
the population of chronic kidney disease (CKD) patients,
OPG was associated with increased cardiovascular mor-
bidity and mortality [18,38,39]. Whether an increase in
OPG during treatment with vitamin D analogs increases
the risk of cardiovascular disease or actually reflects a
vascular protective mechanism, remains to be further
explored.
Left ventricular hypertrophy and cardiac dysfunction
are risk factors for cardiovascular mortality in patients
with CKD [40]. NT-proBNP predicts cardiovascular and
total mortality in hemodialysis patients [41,42]. In ex-
perimental models, vitamin D analogs inhibit left ven-
tricular hypertrophy [12,13]. In the PRIMO trial,
paricalcitol attenuated the increase in BNP compared
with placebo in patients with CKD stages 3–4 [43].
However, in the PRIMO trial and the very similar
OPERA trial [44], paricalcitol did not change the left
ventricular mass index. In post hoc analysis, a reduction
in left atrial volume was detectable after 48 weeks of
paricalcitol treatment, which could be an early marker of
an increase in left ventricular mass [14]. We explored
changes in NT-proBNP during alfacalcidol and paricalci-
tol treatment in hemodialysis patients and found, as in
predialysis patients, a steady increase in NT-proBNP
during the intervention period in both treatment groups.
The increase in Nt-proBNP may have been attenuated
by the vitamin D analogs. Unfortunately, no untreated
group was present.
High levels of parathyroid hormone have been associ-
ated with left ventricular hypertrophy and high levels of
NT-proBNP in patients with CKD and end-stage renal-
disease [45]. This may be due to a direct effect of para-
thyroid hormone on cardiac myocytes [46]. We explored
the relation between changes in PTH during treatment
with vitamin D analogs and changes in NT-proBNP, and
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oidism during 16 weeks of treatment did not influence
changes in NT-proBNP.
FGF23 levels are increased as kidney function declines
[47] and in dialysis patients treatment with vitamin D
analogs increases FGF23 [20]. High FGF23 levels are as-
sociated with increased mortality and left ventricular
hypertrophy in dialysis patients [48,49]. Experimental
studies support that FGF23 induces left ventricular
hypertrophy [50]. We found no relation between changes
in FGF23 during treatment with vitamin D analogs and
changes in NT-proBNP.
The reason why changes in parathyroid hormone or
FGF23 do not relate to changes in NT-proBNP may be
due to the short intervention period or because these
factors are only biomarkers of other mechanisms in-
volved in the pathophysiology of left ventricular hyper-
trophy and heart failure in patients with CKD.
The malnutrition-inflammation complex are common
in dialysis patients and a risk factor for morbidity and
mortality [51]. Experimental studies have demonstrated
an anti-inflammatory effect of vitamin D [9,52]. We did
not find any changes in inflammatory markers during
treatment with alfacalcidol or paricalcitol. These findings
are in conflict with some previous reports. In a placebo-
controlled oral study in CKD stages 1–3 patients [53]
and in two uncontrolled (intravenous and oral) studies
in dialysis patients, a decrease in hs-Crp, IL-6 and TNF-α
was found during paricalcitol treatment [54,55]. However,
Moe et al. did not find any changes in TNF-α or IL-6 after
12 weeks of treatment with intravenous paricalcitol in a
placebo-controlled study in hemodialysis patients with
low PTH [56]. Furthermore, 8 weeks of high-dose chole-
calciferol did not influence inflammatory markers in
predialysis and dialysis patients [57]. Whether an anti-
inflammatory effect of vitamin D and its analogs depends
on the administration route, dose or patient population
including level of hyperparathyroidism, remains to be ex-
plored. Furthermore, the present study may be insuffi-
ciently powered to detect minor changes in inflammatory
parameters.
The present study has several limitations. The study
size was small and minor differences may not be de-
tected. Patients participating in the present study were
comparable with participants in the main study concern-
ing baseline values; still the missing data may lead to
bias, especially in the analysis of uncrossed data. These
prevalent patients may differ from incident dialysis pa-
tients. Other markers, especially ones involved in calcifi-
cation, such as matrix-GLA-protein and osteopontin,
and direct measurement of vascular calcification using
cardiac-CT or abdominal x-ray, may add further infor-
mation to the influence of vitamin D analogs on calcifi-
cation in dialysis patients.Conclusions
Alfacalcidol may increase the calcification inhibitor
fetuin-A compared with paricalcitol in hemodialysis pa-
tients. Alfacalcidol and paricalcitol appear to increase
OPG to a similar extent during treatment, and NT-
proBNP increased equally during both treatments. Both
vitamin D analogs did not influence inflammatory
markers. Whether these findings are important for pa-
tient outcome remains to be further explored.
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